These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31961828)

  • 21. Clinical analysis for 15 patients with pulmonary Langerhans cell histiocytosis and literature review.
    Zhang L; Ouyang R
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):334-343. PubMed ID: 35545326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of BRAF
    Carrere X; Pinto N; Gene Olaciregui N; Galluzzo L; Rossetti E; Celis Passini V; Salvador Marcos N; Chantada G; Braier J; Lavarino C; Felizzia G
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29115. PubMed ID: 33991404
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
    Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
    Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung.
    Kalchiem-Dekel O; Paulk A; Kligerman SJ; Burke AP; Shah NG; Dixon RK
    J Thorac Dis; 2017 Dec; 9(12):E1079-E1083. PubMed ID: 29312770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF-V600E utilizes posttranscriptional mechanisms to amplify LPS-induced TNFα production in dendritic cells in a mouse model of Langerhans cell histiocytosis.
    Minichino D; Lv K; Chu N; Tong W; Behrens EM
    J Leukoc Biol; 2022 Nov; 112(5):1089-1104. PubMed ID: 35648675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
    Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type.
    Wang J; Xie L; Miao Y; Liu X; Tang Y; Xi Y; Chang J; Wu Y; Jiang L
    Ann Transl Med; 2021 Feb; 9(4):357. PubMed ID: 33708984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.
    Nelson DS; Marano RL; Joo Y; Tian SY; Patel B; Kaplan DH; Shlomchik MJ; Stevenson K; Bronson RT; Rollins BJ
    PLoS One; 2019; 14(9):e0222400. PubMed ID: 31527903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bronchoalveolar lavage for the diagnosis of Pulmonary Langerhans cell histiocytosis.
    Lommatzsch M; Bratke K; Stoll P; Mülleneisen N; Prall F; Bier A; Virchow JC
    Respir Med; 2016 Oct; 119():168-174. PubMed ID: 27692140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
    Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
    Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations.
    Yousem SA; Dacic S; Nikiforov YE; Nikiforova M
    Chest; 2013 Jun; 143(6):1679-1684. PubMed ID: 23287985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological features and BRAF
    Huo Z; Lu T; Liang Z; Ping F; Shen J; Lu J; Ma W; Zhao D; Zhong D
    Diagn Pathol; 2016 Oct; 11(1):100. PubMed ID: 27760550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of BRAF-Inhibitor Therapy in BRAF
    Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
    Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.